Speaker

Dr. Xue Tongtong, Founder, Chairman, and CEO of Yilian Biopharmaceuticals, has over 20 years of experience in biopharmaceutical innovation, R&D, and management, encompassing large and small molecule drug design and screening, process development and scale-up, pharmacology and toxicology studies, clinical development, production, and strategic operations. He has led the successful launch of three innovative drug candidates and over 30 projects are currently in clinical and preclinical stages. In the ADC field, he has led the full development of numerous drugs, including B7H3 ADC, HER3 ADC, cMET ADC, and Claudin18.2 ADC, across diverse targets and generations of technology, and has secured numerous licensing agreements. He has published over 10 research papers, including a corresponding author’s paper on B7H3 ADC published in Nature Medicine, and holds over 200 invention patents. He has been recognized with numerous honors, including Jiangsu Province’s Double Innovation Talent, Jiangsu Province’s Industrial Professor, Sichuan Province’s “Thousand Talents Plan” Talent, Chengdu City’s “Young Talent,” Suzhou Major Leading Team Leader, Suzhou Innovation and Entrepreneurship Leading Talent, and Suzhou Industrial Park Innovation and Entrepreneurship Leading Talent.

Prof. Cong Yan is from School of Life Sciences, Beijing University of Chinese Medicine. He is a member of the Academic Committee and serves as the director of the Wei Gao Research Institute and the Center for Traditional Chinese Medicine Inheritance and Digitalization. He is an editorial board member and reviewer for journals such as TMR Modern Traditional Chinese Medicine Journal and Practical Clinical Medicine Journal, as well as serving as an executive council member of the World Federation of Chinese Medicine Societies’ Committee on Evaluation and Promotion of Appropriate Techniques in Traditional Chinese Medicine. Currently, Prof. Yan’s group is focusing on the construction of mathematical and physical system of the traditional Chinese medicine, as well as the development of intelligent traditional Chinese medicine diagnosis and treatment technology. At the same time, Prof. Yan undertakes the school-enterprise combination and achievement transformation work in the field of traditional Chinese medicine, focusing on the fields of smart Chinese medicine diagnosis and treatment equipment, traditional Chinese medicine digital therapy, digital Chinese medicine services, etc.. as well as the industrialization of new clinical technologies, new products of traditional Chinese medicine.

Dr. Yang Guo Tao, a trained pediatrician, transitioned to the pharmaceutical industry in 1998 and has since built a distinguished career spanning over two decades in clinical development. His extensive experience includes a twelve-year tenure at Astellas China, where he served as the Head of Clinical Development. He further honed his expertise in leadership roles at Ferring China for three and a half years and at China Biotech Products for three years, overseeing both clinical development and pharmacovigilance (PV). Most recently, he joined Quarkmed one year ago, bringing his wealth of experience to the organization.

Xiang-numeric science, pioneered by Professor Yang Li, is a discipline that understands the laws of motion of objects through the observation of images and the application of numbers. Its hallmark is “using images to explore the hidden,” using the visible to explore the hidden, rather than using the physical to explore the real. In other words, it is a method of exploring the inner hidden from the external. In other words, it is a science that explores the hidden laws of hidden matter and dark energy. Its advantage is that it doesn’t require physical observation to understand the nature and laws of motion of an object, thus opening up a uniquely Eastern scientific approach comparable to Western empirical science. In short, Eastern Xiang-numeric science and Western empirical science will be on par with each other, complementing and benefiting each other, and together will make significant contributions to human development.

Yang Ming, born in 1968, holds a Bachelor’s degree in Economics and a Master’s degree in Professional Accounting. He is a certified Accountant and a Senior Economist. His previous roles include Project Manager in the Business Management Department of Guotai Securities Co., Ltd., Deputy Manager of the Brokerage Business Headquarters of Guotai Junan Securities Co., Ltd., Manager of the Investment Banking Department at Shanghai Pudong Development Group Finance Co., Ltd., and later Vice General Manager, Party General Branch Secretary, and General Manager of the same company. He also served as a Partner at New Silk Road Investment Co., Ltd., Deputy General Manager of Shanghai Guozhi Investment Management Co., Ltd., Partner at Shanghai Zhihui Investment Co., Ltd., and General Manager of Shanghai Pudong Road & Bridge Construction Co., Ltd. Currently, he serves as Chief Economist of Shanghai Pudong Development (Group) Co., Ltd., Chairman of Shanghai Pudong Construction Co., Ltd., and Director of Shanghai Zhangjiang Haoheng Innovation Equity Investment Management Co., Ltd.

Professor Xiongli Yang obtained a Bachelor’s degree in Biology from Shanghai University of Science and Technology in 1963, and a Ph.D. degree in Neuroscience from Shizuoka University and National Institute for Physiological Sciences, Japan in 1982. He was a foreign fellow at Harvard University (1985-1986), a visiting professor at Baylor College of Medicine (1987-2003). He was appointed as professor in the Shanghai Institute of Physiology, Chinese Academy of Sciences in 1986 and served as director of that institute (1988-1999). He is currently professor at the Institutes of Brain Science, Fudan University. He was elected to the Chinese Academy of Sciences (1991) and the Academy of Sciences for the Developing World (2006). During his long scientific career, he has made an impressive record in the studies of information processing in the retina and the pathogenesis of major retinal diseases, such as myopia and glaucoma, and published more than 250 articles in Science, PNAS, Science Advances, Journal of Neuroscience, Glia, Journal of Physiology, Journal of Neurophysiology, Progress in Neurobiology, Progress in Retinal and Eye Research, etc.

Xuerui Yang’s research group, established in 2012 at Tsinghua University, uses multi-disciplinary approaches for mining of the multi-omics data and dissection of the multi-level gene regulatory programs. He has been particularly interested in the complex world of RNA, such as the post-transcriptional RNA regulation circuits, the translational regulation, and the non-coding RNA functions, under the contexts of complex diseases such as cancer. Dr. Yang’s group has developed a series of bioinformatics algorithms, which in turn provided novel biological insights and led to discoveries of critical translation regulation mechanisms, key regulatory RNAs for normal cell development and tumorigenesis, and noncanonical machineries of post-transcriptional RNA splicing, decay, and modifications.

Dr. Jia Yao, a graduate of Sun Yat-sen University, has over ten years of experience in pharmaceutical solid form research and crystallization process development, including a background in R&D at a large pharmaceutical company. Over many years of research and practice, he has led the solid form research and development of hundreds of new and generic drugs, successfully driving the full development process from pilot trials to full-scale production for many of them. He also possesses profound expertise in crystallography, having independently determined over one hundred small molecule crystal structures, demonstrating his solid technical expertise and extensive project experience.

Mr. Yeung joined Immvira Group in July 2020 and has been serving as the chief financial officer (CFO) of the group since then.

Mr. Yeung has extensive knowledge and more than 20 years’ experience in financial industry. Before joining in Immvira, he held senior management positions at multiple listed corporations, playing a key role in leading their listings on the New York Exchange, NASDAQ and Hong Kong Stock Exchange.

Mr. Yeung received his bachelor’s degree in economics from the Wharton School, University of Pennsylvania, and his bachelor’s degree in applied science from the School of Engineering and Applied Sciences, University of Pennsylvania, in the United States in May 2002.

Dr. Peng Yin, currently is the Chief Scientific Officer (CSO) at Phase Sci. Prior to joining PSI, Dr. Yin was the CTO of Sansure Biotech. Dr. Yin worked in Abbott for over 18 years serving various senior roles: Head of Asia R&D; Head of China R&D; Global Scientific and Medical Affairs Director. Dr. Yin is a Fellow of the AACC Academy (FAACC); previous chair of Industry Division, AACC (ADLM now); Executive Committee Member of the Emerging Technology Division, IFCC; the honorary professor of Tianjin Medical University Cardiovascular Institute and TEDA International Cardiovascular Hospital in China. He is also on the editorial board of both Journal of Human Virology & Retro Virology and Journal of Virology & Current Research. He has published many high-quality scientific research papers in the world’s leading science journals such as Cell, Nature, Science and Journal of Virology. Dr. Peng Yin earned his Medical Doctor Degree (M.D.) from Tianjin Medical School in China and practiced as an abdominal surgeon; earned aa Ph.D. in Molecular Virology from University of Manitoba in Canada. He also completed his postdoctoral training in Virology and oncology at Harvard University Medical School.